Waters Corporation reported fourth-quarter 2018 non-GAAP earnings of $2.87 per share, edging past Zacks Consensus Estimate by 22 cents. The earnings are +14.3% higher compared to the same quarter a year ago.
Net sales of the Analytical laboratory instrument manufacturing company came in at $715.02 million, beating Zacks Consensus Estimate of $702.52 million. Net sales increased +4.1% year-over-year.
Major contributors to sales growth included the company’s TA product line, strong demand in Asia (especially in China), and solid performance in the pharmaceutical market.
For 2019, Waters expects its non-GAAP earnings to be in the range of $9.20-$9.45 per share. It projects net sales to grow between 4% and 6% on a constant currency basis.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for WAT moved out of overbought territory on August 18, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 68 similar instances where the indicator exited the overbought zone. In of the 68 cases the stock moved lower. This puts the odds of a downward move at .
The 10-day RSI Indicator for WAT moved out of overbought territory on August 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for WAT turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
WAT broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on WAT as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
WAT moved above its 50-day moving average on July 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 192 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.655) is normal, around the industry mean (58.245). P/E Ratio (103.975) is within average values for comparable stocks, (155.381). Projected Growth (PEG Ratio) (1.793) is also within normal values, averaging (1.736). WAT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (6.623) is also within normal values, averaging (10.493).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties